Chronic Lymphocytic Leukemia | Exploring Clinical Investigator Perspectives on the Optimal Management of Chronic Lymphocytic Leukemia (for Hematology-Oncology Fellows)

Featuring perspectives from Dr Jennifer Woyach, including the following topics: Front-line therapy for chronic lymphocytic leukemia (CLL) for fellows; use of prognostic biomarkers and cytogenetics in refining risk assessment for patients with newly diagnosed disease — Jennifer Woyach, MD (0:00) Bruton tyrosine kinase (BTK) inhibitors for treatment-naïve CLL (8:29) Venetoclax/obinutuzumab for treatment-naïve disease; overview of patient selection for chemoimmunotherapy (18:04) Relevant biomarkers influencing the selection of therapy for patients with CLL (24:09) Impact of biologic and patient-related factors on front-line decision-making (30:24) Selection and sequencing of therapies for relapsed/refractory CLL (1:02:53) Key considerations and take-home messages (1:13:52) CME information and select publications